| Nov 14 |
Candel Therapeutics reports Q3 results
|
| Nov 14 |
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 7 |
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
|
| Nov 5 |
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
|
| Nov 1 |
Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think
|
| Oct 29 |
Candel Therapeutics Advances in Cancer Treatment Trials
|
| Oct 28 |
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
|
| Oct 4 |
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
|
| Sep 13 |
Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%
|
| Sep 4 |
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
|
